Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Autism drug trial pulled before it even started

NCT ID NCT02947880

Disease control Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study planned to test the drug bumetanide in children aged 5 to 17 with autism of known cause. The goal was to see if it could improve autism symptoms. However, the trial was withdrawn before enrolling any participants, so no new information was gathered.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bumetanide
What this could lead to
If it worked, bumetanide might help reduce autism symptoms in some children.
What could go wrong
The trial was withdrawn before any participants enrolled, so no results are available. Earlier positive findings were small and need more confirmation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Started

Dec 2016

Finished

Jun 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children and teenager from age 5 to age 17, with a diagnosis of typical autism or Asperger syndrome according to the criteria of diagnosis of the WHO's classification (CIM-10), * With a known etiology, * Patients for whom the CARS results are strictly Superior or equal to 30, * Of whom the parents have given their free, informed and written consent, * Affiliated or beneficiary of the French social security. Exclusion Criteria: * Patients under treatment by inlet diuretic either at the time of the study or before, * Patients with electrolytic disorders, * Patients with a known hypersensitivity to sulfa drugs, * Patients with a hepatic or renal failure, * Patients with an epilepsy not controlled by a treatment (comitial crisis in the past 6 month at the time the trial starts despite a treatment), * Patients under treatment by psychotropic exception made of the melatonin, * Allergy to the bumetanide or one of its excipients, * Patient under a treatment by lithium, diphemanil, erythromycin IV, halofantrine, pentamidine, sultopride, vincamine, aminoglycoside, * Pregnant and lactating women. Secondary exclusion criteria: * QT prolongation noticed on the ECG at Day0, * Anomaly on the biological check up (Day 0) made before including the patient that would contraindicated the prescription of bumetanide, * Patients for whom the CARS results are strictly inferior to 30.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autistic disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autistic disorder

Contacts and locations

Locations

  • CHU de Limoges

    Limoges, 87042, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.